Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A 12-month, Phase III, Randomized, Double-masked, Multicenter, Active-controlled Study to Evaluate the Efficacy and Safety of Two Individualized Regimens of 0.5mg Ranibizumab vs. Verteporfin PDT in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia

Trial Profile

A 12-month, Phase III, Randomized, Double-masked, Multicenter, Active-controlled Study to Evaluate the Efficacy and Safety of Two Individualized Regimens of 0.5mg Ranibizumab vs. Verteporfin PDT in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 07 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ranibizumab (Primary) ; Verteporfin (Primary)
  • Indications Choroidal neovascularisation; Degenerative myopia
  • Focus Registrational; Therapeutic Use
  • Acronyms Brilliance
  • Sponsors Novartis Pharmaceuticals Corporation

Most Recent Events

  • 17 Oct 2016 Status changed from recruiting to completed.
  • 12 Jan 2016 Planned End Date changed from 1 Oct 2016 to 1 Sep 2016 as reported by ClinicalTrials.gov.
  • 12 Jan 2016 Planned primary completion date changed from 1 Oct 2016 to 1 Sep 2016 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top